Best First-Line Antidepressant for Major Depressive Disorder
Select a second-generation antidepressant based on adverse effect profile, cost, and patient preferences—with sertraline or escitalopram being the strongest evidence-based choices for initial therapy. 1, 2
The Evidence-Based Approach
The American College of Physicians guideline establishes that no second-generation antidepressant demonstrates superior efficacy over another for treating acute major depression 1. All SSRIs, SNRIs, and other second-generation agents show equivalent effectiveness across age, sex, and racial/ethnic subgroups. This means your selection should pivot on three factors: adverse effects, cost, and what the patient values most.
Specific Drug Recommendations
Top-Tier Choices
Sertraline emerges as the single best option when balancing efficacy, tolerability, and cost 2, 3. A multiple-treatments meta-analysis of 117 trials (25,928 participants) found sertraline and escitalopram demonstrated the best acceptability profiles, with significantly fewer discontinuations than duloxetine, fluvoxamine, paroxetine, reboxetine, and venlafaxine 2. Sertraline specifically showed superior efficacy to fluoxetine (NNT=12) and other SSRIs as a class (NNT=17) at 8 weeks 3.
Escitalopram ranks as the co-first choice, showing equivalent acceptability to sertraline and superior efficacy compared to duloxetine, fluoxetine, fluvoxamine, and paroxetine 2.
Symptom-Specific Selection
When predominant symptoms guide your choice:
- Anxiety symptoms: Start with escitalopram or sertraline 4
- Loss of interest/motivation: Consider duloxetine or venlafaxine 4
- Insomnia, loss of appetite, or suicidal ideation: Mirtazapine becomes first-line 4
- Sexual dysfunction concerns: Choose bupropion, which has significantly lower rates of sexual adverse events than fluoxetine or sertraline 1
Drugs to Avoid as First-Line
Paroxetine should not be your initial choice—it carries higher rates of sexual dysfunction than fluoxetine, fluvoxamine, nefazodone, or sertraline 1. It also has more anticholinergic effects and is specifically discouraged in older adults 5.
Reboxetine demonstrated significantly inferior efficacy compared to all other tested antidepressants 2.
Critical Safety Monitoring
Begin monitoring within 1-2 weeks of initiation 1. SSRIs carry an increased risk for suicide attempts compared to placebo, with the highest risk during the first 1-2 months of treatment 1. Watch specifically for agitation, irritability, or unusual behavioral changes indicating worsening depression.
When to Modify Treatment
Reassess at 6-8 weeks—if inadequate response occurs, modify the regimen 1. Response rates to initial antidepressant therapy may be as low as 50%, with 54% failing to achieve remission 1.
For non-response to an SSRI, switch to either an SNRI or mirtazapine 4. For non-response to an SNRI, switch to mirtazapine 4. Augmentation with aripiprazole represents first-line strategy for partial response to SSRIs or SNRIs 4.
Duration of Treatment
Continue for 4-9 months after achieving satisfactory response in first-episode depression 1. For patients with 2+ prior episodes, extend treatment duration—recurrence risk escalates from 50% after one episode to 70% after two episodes and 90% after three 5.
Common Pitfalls to Avoid
- Don't use fluoxetine in older adults due to greater agitation risk 5
- Don't select paroxetine for elderly patients given anticholinergic burden 5
- Don't wait beyond 6-8 weeks to modify inadequate treatment 1
- Don't discontinue at end of acute phase—this fails to prevent relapse 5
The Bottom Line Algorithm
- Start with sertraline (50-200 mg/day) for most patients—best evidence for efficacy and tolerability balance
- Use escitalopram (10-20 mg/day) as equivalent alternative
- Choose mirtazapine (15-45 mg/day) when insomnia, appetite loss, or suicidal ideation predominate
- Select bupropion (100-400 mg/day SR) when sexual function preservation is priority
- Monitor at 1-2 weeks, then regularly through first 2 months
- Reassess at 6-8 weeks—switch or augment if inadequate response
- Continue 4-9 months after remission (longer for recurrent depression)
The most recent ACP guideline 6 from 2023 confirms cognitive behavioral therapy as equivalent monotherapy option, but when pharmacotherapy is chosen, these medication selection principles remain the evidence-based standard.